Upstream Bio (UPB) Revenue & Revenue Breakdown
Upstream Bio Revenue Highlights
Latest Revenue (Y)
$2.37M
Latest Revenue (Q)
$683.00K
Upstream Bio Revenue by Period
Upstream Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $2.37M | -0.42% |
| 2023-12-31 | $2.38M | 96.37% |
| 2022-12-31 | $1.21M | - |
Upstream Bio generated $2.37M in revenue during NA 2024, up -0.42% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Upstream Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $683.00K | -27.11% |
| 2025-06-30 | $937.00K | 65.55% |
| 2025-03-31 | $566.00K | -7.67% |
| 2024-12-31 | $613.00K | 0.99% |
| 2024-09-30 | $607.00K | 19.02% |
| 2024-06-30 | $510.00K | -20.31% |
| 2024-03-31 | $640.00K | 42.22% |
| 2023-12-31 | $450.00K | -27.54% |
| 2023-09-30 | $621.00K | - |
Upstream Bio generated $683.00K in revenue during Q3 2025, up -27.11% compared to the previous quarter, and up 133.92% compared to the same period a year ago.
Upstream Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NVAX | Novavax | $682.16M | $70.44M |
| WVE | Wave Life Sciences | $108.30M | $7.61M |
| AMLX | Amylyx Pharmaceuticals | $87.37M | - |
| SNDX | Syndax Pharmaceuticals | $23.68M | $45.87M |
| RLAY | Relay Therapeutics | $10.01M | - |
| ZBIO | Zenas BioPharma | $5.00M | - |
| UPB | Upstream Bio | $2.37M | $683.00K |
| NTLA | Intellia Therapeutics | - | $13.78M |
| PHVS | Pharvaris | - | - |
| SYRE | Spyre Therapeutics | - | - |
| TERN | Terns Pharmaceuticals | - | - |